LivaNova $345 million equity offering
We advised the underwriters on the SEC-registered offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of 4,181,818 ordinary shares of LivaNova PLC. Included in the shares are 545,454 shares sold by LivaNova PLC pursuant to the underwriters’ exercise in full of their option to acquire additional shares. The gross proceeds from the offering were approximately $345 million. The ordinary shares are listed on the Nasdaq Global Market under the symbol “LIVN.”
Headquartered in London, United Kingdom, LivaNova PLC is a global medical device company focused on the development and delivery of important therapeutic solutions in the fields of cardiovascular disease and neuromodulation for the benefit of patients, healthcare professionals and healthcare systems throughout the world.
The Davis Polk corporate team included partners Marcel Fausten, Simon Witty and Dan Hirschovits, European counsel John Taylor and associates Johnathan M. Nixon and Xi (Brooke) Zheng. The tax team included partners Michael Farber and Jonathan Cooklin, counsel Dominic Foulkes and associate Ben Levenback. Members of the Davis Polk team are based in the New York and London offices.